A pharmaceutical composition comprising FLT3 inhibitor and MDM2 inhibitor for the treatment of the acute myeloid leukemia

摘要

Fms-like tyrosine kinase-3 (FLT3) inhibitors, pharmaceutically acceptable salts thereof, or solvates thereof, and murine double minute 2 (MDM2) inhibitors, pharmaceuticals thereof It provides a pharmaceutical composition for the treatment of acute myeloid leukemia (AML), and a method for treating acute myelogenous leukemia using the same, comprising an acceptable salt or a solvate thereof in a therapeutically effective combination.